Lidocaine Adverse ReactionPhase 3CO2NCT03366246
Efficacy of a Topical Anesthetic Containing Lidocaine and Prilocaine in Treatment With CO2 Fractional Laser
A Phase 3 study testing Lidocaine / Prilocaine Cream in people with Lidocaine Adverse Reaction and Prilocaine Adverse Reaction, run by Galeno Desenvolvimento de Pesquisas Clínicas at 1 site in Brazil.
Trial summary
This is a study aimed at evaluating the efficacy of a topical anesthesia (test product) compared to placebo in adult patients of phototypes I to III, with indication of treatment of CO2 fractional laser in the forehead. In addition to efficacy, safety and tolerability of the product have been studied. Read more about this study
- Who is it for?
- Ages 18 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Lidocaine Adverse Reaction, Prilocaine Adverse Reaction
- What is being tested?
- Lidocaine / Prilocaine Cream
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 120 participants
- Where
- 1 siteBrazil
- Study dates
- 7 Jun 2014to 25 Jul 2014
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Female or male patients with phototypes I to III and older than 18 years and less than 70 years;
- Indication of aesthetic treatment with CO2 fractional laser in the forehead;
- Absence of treatment in the forehead that, at the discretion of the clinical investigator, may interfere with the objectives of the study;
- Absence of allergic skin reactions on the face;
- Lack of other significant diseases that, according to the criteria defined in this protocol, may be impacted by the medical criteria, and the evaluations to which it was submitted: clinical history, physical examination, ECG;
- Capable of understanding the nature and purpose of the study, including risks and adverse effects, and intending to cooperate with the researcher and to act according to the requirements of the entire study, by signing the Informed Consent Form.
Who cannot join
- The volunteer has known hypersensitivity to chemically related compounds; history of serious adverse reactions or hypersensitivity to any drug;
- Known hypersensitivity to lidocaine, prilocaine, vehicle of the investigational product (gel) or to chemically related compounds; history of serious adverse reactions;
- History of congenital or idiopathic methemoglobinemia
- Current evidence of clinically significant diseases of gastrointestinal, cardiovascular, hepatic, renal, pulmonary, or other origin that prevent patient participation in the study and / or, at the discretion of the clinical investigator, expose the patient to additional risk ;
- History of alcohol or drug abuse;
- Treatment, within 3 months prior to the study, with any drug known to have a well-defined toxic potential in large organs;
- Participation in any experimental study or ingestion of any experimental drug within six months prior to the start of this study; 8 .Positive pregnancy test , delivery or abortion in the 12 weeks prior to the scheduled start of treatment; 9 .Any condition that prevents the patient from participating in the study, according to the researcher's criteria.
Trial locations and contacts
1 site in 1 country.
Brazil1 site
Clinica Gobbato de Medicina e Dermatologia
Rio Claro, São Paulo, 13501105
About this study
Official title: A Double-blind, Monocentric, Phase 3 Clinical Study for the Evaluation of Efficacy of a Topical Anesthetic Containing Lidocaine 25mg/g and Prilocaine 25mg/g in Adult Patients of Phototypes I to III in Treatment With CO2 Fractional Laser
This is a study aimed at evaluating the efficacy of a topical anesthesia (test product) compared to placebo in adult patients of phototypes I to III, with indication of treatment of CO2 fractional laser in the forehead. In addition to efficacy, safety and tolerability of the product have been studied.
The product under investigation is a topical formulation containing lidocaine 25 mg/g and prilocaine 25mg/g which in previous studies performed in the same institution with healthy subjects in adulthood showed faster onset than other formulations. In these previous studies, the product was well tolerated, and there were no signs of a skin reaction or adverse events of a systemic nature.
Read more
The CO2 fractional laser treatment is routinely used by plastic surgery and dermatology for treatment with aesthetic purposes of skin imperfections. It's a procedure until certain painful point, which as a rule is performed without prior use of topical anesthetic.
The test product is believed to produce a clinically significant reduction of pain when compared to placebo, during the application of CO2 laser on the forehead for the aesthetic treatment of the face.
Read the detailed description
The study was designed to allow assessing the efficacy of the product compared to placebo when applied to reduce pain resulting from treatment of the forehead with CO2 fractional laser at 5 mJ fluency and 5% concentration. To assess possible reactions, the photographic records were taken prior to the application of both products, as well as immediately prior to laser therapy and after 1 hour of laser therapy (1:20 h of application of the products).
In addition to the efficacy evaluation, the concomitant application of the control product (placebo) aimed to verify if possible dermatological reactions would be related to the active principle of the product or to the components of the cream base or to the performance of the laser therapy. In addition, considering a subgroup of participants, the study allowed the assessment of the degree of systemic absorption from the plasma concentrations observed, through the collection of blood samples for quantification of the compounds after their topical application.
Phase III, double-blind, monocentric, randomized crossover at the same time (right and left sides of forehead) , consisting of 120 patients, phototypes I to III, older than 18 years, female or male, with indication of aesthetic treatment with carbon dioxide (CO2) fractional laser in the forehead.
The anesthetic formulation, the object of the study, was administered topically in one side of the forehead and the placebo formulation (vehicle of the product) in the opposite side, once, as randomized, twenty minutes before the start of the CO2 laser therapy (in both sides of the forehead).
A total of 120 samples (5 g tubes) of the Test formulation and 120 samples (5 g tubes) of the Control (placebo) formulation were prepared for the administration of the medication to study . Initially, based on identification only on the secondary packaging (labeled plastic bag containing only test formulation tubes and labeled plastic bag containing only control formulation tubes), the tubes of each formulation were labeled with the subject's subject number and the indication of the side ( left or right ) of application, according to randomization of the study. After labeling and proper conferencing, these identical looking tubes were assembled and sorted by the participant number and left or right , and it was no longer possible to distinguish whether a particular tube concerned the test or control formulation. This set of samples was forwarded for conducting the study. Those responsible for the separation did not participate in the conduct of the study activities.
The study population consisted of female or male patients, phototypes I to III, with good general health conditions and those older than 18 years who had indication of aesthetic treatment with CO2 fractional laser compatible with the study proposal . These patients attended the clinic either spontaneously.
The anesthetic formulation and placebo were weighed individually, 2g of each gel, placing them directly on a spatula identified as left or right side, on a semi-analytical scale. The contents on the spatulas were applied to the corresponding forehead side using the gloved finger of the applicator to spread it as evenly as possible, 20 minutes before the session with CO2 fractional laser, under the supervision of the clinical investigator. Both test product and placebo gel were removed with saline solution and then CO2 laser intensity of 5mJ and concentration of 5% was applied across the forehead, always starting the right side toward the left side.
Immediately (0 min) after laser application and at 30, 60 and 90 minutes, it was assessed pain sensation in four quadrants of each forehead side using a visual analogue scale. The scale consists of a continuous line, whose left end corresponding to the absence of pain ("No Pain") and right end corresponding to the worst pain bearable by the patient ("the worst pain you can imagine"). The patient scored a perpendicular mark anywhere on the line (including the ends) in position to understand better represent the intensity of pain experienced on that quadrant at the specific time of each evaluation.
The evaluations were completed after 90 minutes of laser session (110 minutes after treatment with the investigational products) and blood pressure, pulse and temperature measurements were performed before the patient was released. At the end of the study, the distance from the left end to the mark was measured with a millimeter scale ruler. Two independent persons performed this measurement and any discrepancies values were conferred by a third person.
At the end of the procedure was generated a table in Excel, also conferred with the values obtained in centimeters for each occasion, including the total length of the ruler. The value in percentage was obtained by dividing the measured value by the total length of the scale by 100 . The averaged response corresponding to the four quadrants on the left and the average of the responses corresponding to the four quadrants on the right was calculated.
The two values (mean of the left side and mean of the right side) obtained for each of the occasions was the value used for the statistical calculation of treatment efficacy. A mean reduction of 30% with the topical anesthetic versus placebo - test / placebo ≤0.7 was considered clinically significant . The statistical analysis used for efficacy was the paired t-test.
- Being tested
- Lidocaine / Prilocaine Cream, placebo
- Keywords
- topical anesthetic, nanocapsules, nanotechnology, lidocaine, prilocaine, fractional CO2 laser resurfacing
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lidocaine / Prilocaine CreamDrug
according randomized this side received placebo or active product
placeboDrug
according randomized this side received placebo or active product
| Study group | Role | What they receive |
|---|---|---|
| lidocaine / prilocaine cream | Active comparator | according to randomization 2g topical nano anesthetic ( lidocaine 25mg/g and prilociane 25mg/g )was applied to one side ( left or right ) of the forehead 20 minutes before laser therapy. Receives: Drug: Lidocaine / Prilocaine Cream |
| placebo | Placebo comparator | according to randomization 2g of the placebo( nano anesthetic vehicle with no active ingredient ) was applied to one side ( left or right) of the forehead 20 minutes before laser therapy. Receives: Drug: placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pain assessed by means of a visual analog scale
The aim of this present study was to evaluate the efficacy of this new product compared to placebo when applied to the forehead of patients submitted to fractional CO2 laser, using a visual analog scale (VAS).The scale consists of a continuous line, whose left end corresponding to the absence of pain ("No Pain") and right end corresponding to the worst pain bearable by the patient ("the worst pain you can imagine"). The patient scored a perpendicular mark anywhere on the line (including the ends) in position to understand better represent the intensity of pain experienced on that quadrant at the specific time of each evaluation
Measured: at 0 minutes after laser therapy with CO2 fractional laser.
Pain assessed by means of a visual analog scale
The aim of this present study was to evaluate the efficacy of this new product compared to placebo when applied to the forehead of patients submitted to fractional CO2 laser, using a visual analog scale (VAS).The scale consists of a continuous line, whose left end corresponding to the absence of pain ("No Pain") and right end corresponding to the worst pain bearable by the patient ("the worst pain you can imagine"). The patient scored a perpendicular mark anywhere on the line (including the ends) in position to understand better represent the intensity of pain experienced on that quadrant at the specific time of each evaluation.
Measured: at 30 minutes after laser therapy with CO2 fractional laser.
Pain assessed by means of a visual analog scale
The aim of this present study was to evaluate the efficacy of this new product compared to placebo when applied to the forehead of patients submitted to fractional CO2 laser, using a visual analog scale (VAS).The scale consists of a continuous line, whose left end corresponding to the absence of pain ("No Pain") and right end corresponding to the worst pain bearable by the patient ("the worst pain you can imagine"). The patient scored a perpendicular mark anywhere on the line (including the ends) in position to understand better represent the intensity of pain experienced on that quadrant at the specific time of each evaluation.
Measured: at 60 minutes after laser therapy with CO2 fractional laser
Pain assessed by means of a visual analog scale
The aim of this present study was to evaluate the efficacy of this new product compared to placebo when applied to the forehead of patients submitted to fractional CO2 laser, using a visual analog scale (VAS).The scale consists of a continuous line, whose left end corresponding to the absence of pain ("No Pain") and right end corresponding to the worst pain bearable by the patient ("the worst pain you can imagine"). The patient scored a perpendicular mark anywhere on the line (including the ends) in position to understand better represent the intensity of pain experienced on that quadrant at the specific time of each evaluation.
Measured: at 90 minutes after laser therapy with CO2 fractional laser
Secondary outcomes (1)
Adverse Event Incidence
As secondary objective were to evaluate the safety of possible dermatological reactions
Measured: at 0:50, 1:20 and 1:50 minutes after cream application
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Dec 2017
- Study start7 Jun 2014
- Primary completion25 Jul 2014
- Study completion25 Jul 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lidocaine Adverse ReactionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Double-blind, crossover study where the same participant received in one side of the forehead the active drug and in the other side of the forehead placebo.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 120 participants (actual)
Sponsor and investigators
- Lead sponsor
- Galeno Desenvolvimento de Pesquisas Clínicas
- Sponsor type
- Other government
- Collaborators
- Biolab Sanus Farmaceutica
- Responsible party
- Principal investigator, Gilberto De Nucci, Galeno Desenvolvimento de Pesquisas Clínicas
- Investigators
- Gilberto De Nucci, MD, Study director, Galeno Desenvolvimento de Pesquisas Clinicas Ltda. - ME
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03366246
- Sponsor's protocol ID
- GDN 051/13
- Acronym
- CO2
- Status last verified
- Dec 2017
- First submitted
- 22 Nov 2017
- Last updated
- 8 Dec 2017
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: study protocol results
Study at a glance
From the registry record, last updated by the sponsor on 8 Dec 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Double-blind, Monocentric, Phase 3 Clinical Study for the Evaluation of Efficacy of a Topical Anesthetic Containing Lidocaine 25mg/g and Prilocaine 25mg/g in Adult Patients of Phototypes I to III in Treatment With CO2 Fractional Laser
- ClinicalTrials.gov ID
- NCT03366246
- Acronym / sponsor ID
- CO2 / GDN 051/13
- Keywords
- topical anesthetic, nanocapsules, nanotechnology, lidocaine, prilocaine, fractional CO2 laser resurfacing
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 120 participants (actual)
- Lead sponsor
- Galeno Desenvolvimento de Pesquisas ClínicasOther government
- Collaborators
- Biolab Sanus Farmaceutica
- Study start
- 7 Jun 2014 (actual)
- Primary completion
- 25 Jul 2014 (actual)
- Study completion
- 25 Jul 2014 (actual)
- First posted
- 8 Dec 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a study aimed at evaluating the efficacy of a topical anesthesia (test product) compared to placebo in adult patients of phototypes I to III, with indication of treatment of CO2 fractional laser in the forehead. In addition to efficacy, safety and tolerability of the product have been studied.
The product under investigation is a topical formulation containing lidocaine 25 mg/g and prilocaine 25mg/g which in previous studies performed in the same institution with healthy subjects in adulthood showed faster onset than other formulations. In these previous studies, the product was well tolerated, and there were no signs of a skin reaction or adverse events of a systemic nature.
The CO2 fractional laser treatment is routinely used by plastic surgery and dermatology for treatment with aesthetic purposes of skin imperfections. It's a procedure until certain painful point, which as a rule is performed without prior use of topical anesthetic.
The test product is believed to produce a clinically significant reduction of pain when compared to placebo, during the application of CO2 laser on the forehead for the aesthetic treatment of the face.
Detailed description
The study was designed to allow assessing the efficacy of the product compared to placebo when applied to reduce pain resulting from treatment of the forehead with CO2 fractional laser at 5 mJ fluency and 5% concentration. To assess possible reactions, the photographic records were taken prior to the application of both products, as well as immediately prior to laser therapy and after 1 hour of laser therapy (1:20 h of application of the products).
In addition to the efficacy evaluation, the concomitant application of the control product (placebo) aimed to verify if possible dermatological reactions would be related to the active principle of the product or to the components of the cream base or to the performance of the laser therapy. In addition, considering a subgroup of participants, the study allowed the assessment of the degree of systemic absorption from the plasma concentrations observed, through the collection of blood samples for quantification of the compounds after their topical application.
Phase III, double-blind, monocentric, randomized crossover at the same time (right and left sides of forehead) , consisting of 120 patients, phototypes I to III, older than 18 years, female or male, with indication of aesthetic treatment with carbon dioxide (CO2) fractional laser in the forehead.
The anesthetic formulation, the object of the study, was administered topically in one side of the forehead and the placebo formulation (vehicle of the product) in the opposite side, once, as randomized, twenty minutes before the start of the CO2 laser therapy (in both sides of the forehead).
A total of 120 samples (5 g tubes) of the Test formulation and 120 samples (5 g tubes) of the Control (placebo) formulation were prepared for the administration of the medication to study . Initially, based on identification only on the secondary packaging (labeled plastic bag containing only test formulation tubes and labeled plastic bag containing only control formulation tubes), the tubes of each formulation were labeled with the subject's subject number and the indication of the side ( left or right ) of application, according to randomization of the study. After labeling and proper conferencing, these identical looking tubes were assembled and sorted by the participant number and left or right , and it was no longer possible to distinguish whether a particular tube concerned the test or control formulation. This set of samples was forwarded for conducting the study. Those responsible for the separation did not participate in the conduct of the study activities.
The study population consisted of female or male patients, phototypes I to III, with good general health conditions and those older than 18 years who had indication of aesthetic treatment with CO2 fractional laser compatible with the study proposal . These patients attended the clinic either spontaneously.
The anesthetic formulation and placebo were weighed individually, 2g of each gel, placing them directly on a spatula identified as left or right side, on a semi-analytical scale. The contents on the spatulas were applied to the corresponding forehead side using the gloved finger of the applicator to spread it as evenly as possible, 20 minutes before the session with CO2 fractional laser, under the supervision of the clinical investigator. Both test product and placebo gel were removed with saline solution and then CO2 laser intensity of 5mJ and concentration of 5% was applied across the forehead, always starting the right side toward the left side.
Immediately (0 min) after laser application and at 30, 60 and 90 minutes, it was assessed pain sensation in four quadrants of each forehead side using a visual analogue scale. The scale consists of a continuous line, whose left end corresponding to the absence of pain ("No Pain") and right end corresponding to the worst pain bearable by the patient ("the worst pain you can imagine"). The patient scored a perpendicular mark anywhere on the line (including the ends) in position to understand better represent the intensity of pain experienced on that quadrant at the specific time of each evaluation.
The evaluations were completed after 90 minutes of laser session (110 minutes after treatment with the investigational products) and blood pressure, pulse and temperature measurements were performed before the patient was released. At the end of the study, the distance from the left end to the mark was measured with a millimeter scale ruler. Two independent persons performed this measurement and any discrepancies values were conferred by a third person.
At the end of the procedure was generated a table in Excel, also conferred with the values obtained in centimeters for each occasion, including the total length of the ruler. The value in percentage was obtained by dividing the measured value by the total length of the scale by 100 . The averaged response corresponding to the four quadrants on the left and the average of the responses corresponding to the four quadrants on the right was calculated.
The two values (mean of the left side and mean of the right side) obtained for each of the occasions was the value used for the statistical calculation of treatment efficacy. A mean reduction of 30% with the topical anesthetic versus placebo - test / placebo ≤0.7 was considered clinically significant . The statistical analysis used for efficacy was the paired t-test.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Double-blind, crossover study where the same participant received in one side of the forehead the active drug and in the other side of the forehead placebo.
| Arm | Type | Receives |
|---|---|---|
| lidocaine / prilocaine cream | Active comparator | Drug: Lidocaine / Prilocaine Creamaccording to randomization 2g topical nano anesthetic ( lidocaine 25mg/g and prilociane 25mg/g )was applied to one side ( left or right ) of the forehead 20 minutes before laser therapy. |
| placebo | Placebo comparator | Drug: placeboaccording to randomization 2g of the placebo( nano anesthetic vehicle with no active ingredient ) was applied to one side ( left or right) of the forehead 20 minutes before laser therapy. |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Female or male patients with phototypes I to III and older than 18 years and less than 70 years;
- Indication of aesthetic treatment with CO2 fractional laser in the forehead;
- Absence of treatment in the forehead that, at the discretion of the clinical investigator, may interfere with the objectives of the study;
- Absence of allergic skin reactions on the face;
- Lack of other significant diseases that, according to the criteria defined in this protocol, may be impacted by the medical criteria, and the evaluations to which it was submitted: clinical history, physical examination, ECG;
Key exclusion criteria (7 listed)
- The volunteer has known hypersensitivity to chemically related compounds; history of serious adverse reactions or hypersensitivity to any drug;
- Known hypersensitivity to lidocaine, prilocaine, vehicle of the investigational product (gel) or to chemically related compounds; history of serious adverse reactions;
- History of congenital or idiopathic methemoglobinemia
- Current evidence of clinically significant diseases of gastrointestinal, cardiovascular, hepatic, renal, pulmonary, or other origin that prevent patient participation in the study and / or, at the discretion of the clinical investigator, expose the patient to additional risk ;
- History of alcohol or drug abuse;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Lidocaine / Prilocaine Creamaccording randomized this side received placebo or active product | Drug | lidocaine / prilocaine cream |
| placeboaccording randomized this side received placebo or active product | Drug | placebo |
Primary outcome
Pain assessed by means of a visual analog scale
Time frame: at 0 minutes after laser therapy with CO2 fractional laser.
The aim of this present study was to evaluate the efficacy of this new product compared to placebo when applied to the forehead of patients submitted to fractional CO2 laser, using a visual analog scale (VAS).The scale consists of a continuous line, whose left end corresponding to the absence of pain ("No Pain") and right end corresponding to the worst pain bearable by the patient ("the worst pain you can imagine"). The patient scored a perpendicular mark anywhere on the line (including the ends) in position to understand better represent the intensity of pain experienced on that quadrant at the specific time of each evaluation
Pain assessed by means of a visual analog scale
Time frame: at 30 minutes after laser therapy with CO2 fractional laser.
The aim of this present study was to evaluate the efficacy of this new product compared to placebo when applied to the forehead of patients submitted to fractional CO2 laser, using a visual analog scale (VAS).The scale consists of a continuous line, whose left end corresponding to the absence of pain ("No Pain") and right end corresponding to the worst pain bearable by the patient ("the worst pain you can imagine"). The patient scored a perpendicular mark anywhere on the line (including the ends) in position to understand better represent the intensity of pain experienced on that quadrant at the specific time of each evaluation.
Pain assessed by means of a visual analog scale
Time frame: at 60 minutes after laser therapy with CO2 fractional laser
The aim of this present study was to evaluate the efficacy of this new product compared to placebo when applied to the forehead of patients submitted to fractional CO2 laser, using a visual analog scale (VAS).The scale consists of a continuous line, whose left end corresponding to the absence of pain ("No Pain") and right end corresponding to the worst pain bearable by the patient ("the worst pain you can imagine"). The patient scored a perpendicular mark anywhere on the line (including the ends) in position to understand better represent the intensity of pain experienced on that quadrant at the specific time of each evaluation.
Pain assessed by means of a visual analog scale
Time frame: at 90 minutes after laser therapy with CO2 fractional laser
The aim of this present study was to evaluate the efficacy of this new product compared to placebo when applied to the forehead of patients submitted to fractional CO2 laser, using a visual analog scale (VAS).The scale consists of a continuous line, whose left end corresponding to the absence of pain ("No Pain") and right end corresponding to the worst pain bearable by the patient ("the worst pain you can imagine"). The patient scored a perpendicular mark anywhere on the line (including the ends) in position to understand better represent the intensity of pain experienced on that quadrant at the specific time of each evaluation.
1 secondary outcome
Adverse Event Incidence
Time frame: at 0:50, 1:20 and 1:50 minutes after cream application
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Dec 2017.
- Individual participant dataSharing planned: Undecided. study protocol results
Related trials for Lidocaine Adverse Reaction
RecruitingPhase 3
LIMIT Trial - Lidocaine With Intramuscular Injection of Benzathine Penicillin G for Treponema Pallidum Treatment
Syphilis Infection, Benzathine Penicillin Adverse Reaction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gilberto De Nucci, MD study director
Galeno Desenvolvimento de Pesquisas Clinicas Ltda. - ME
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Lidocaine / Prilocaine Cream in people with Lidocaine Adverse Reaction and Prilocaine Adverse Reaction, run by Galeno Desenvolvimento de Pesquisas Clínicas at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Dec 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pain assessed by means of a visual analog scale (time frame: at 0 minutes after laser therapy with CO2 fractional laser.). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Dec 2017.